Bloodstream Infections in Hospitalized Children: Epidemiology and Antimicrobial Susceptibilities

The Pediatric Infectious Disease Journal
Beatriz LarruJeffrey S Gerber

Abstract

Bloodstream infection is a major cause of morbidity and mortality. Much of our understanding of the epidemiology and resistance patterns of bloodstream infections comes from studies of hospitalized adults. We evaluated the epidemiology and antimicrobial resistance of bloodstream infections occurring during an 11-year period in a large, tertiary care children's hospital in the US. All positive blood cultures were identified retrospectively from clinical microbiology laboratory records. We excluded repeat positive cultures with the same organism from the same patient within 30 days and polymicrobial infections. We identified 8196 unique episodes of monomicrobial bacteremia in 5508 patients. Overall, 46% were community onset, 72% were Gram-positive bacteria, 22% Gram-negative bacteria and 5% Candida spp. Coagulase negative Staphylococcus was the most common isolated organism. ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) accounted for 20% of episodes. No S. aureus isolate was resistant to vancomycin or linezolid, and no increase in vancomycin minimum inhibitory concentration among methicillin-resistant S. aureus was obser...Continue Reading

References

May 3, 2001·The Pediatric Infectious Disease Journal·J GrayK Morris
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yardena Siegman-IgraMichael Giladi
Aug 13, 2003·The Pediatric Infectious Disease Journal·Hilmar WisplinghoffMichael B Edmond
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Apr 20, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ebbing Lautenbach, Irving Nachamkin
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
Apr 23, 2013·The Journal of Antimicrobial Chemotherapy·Philippe R S Lagacé-WiensUNKNOWN Canadian Antimicrobial Resistance Alliance
Apr 23, 2013·The Journal of Antimicrobial Chemotherapy·James A KarlowskyUNKNOWN Canadian Antimicrobial Resistance Alliance
Jul 11, 2013·Acta Paediatrica·Andrés Pérerz LopézMike Sharland
Nov 13, 2013·Pediatrics·Eric BiondiFrancis Gigliotti
Nov 15, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Pranita D TammaAaron M Milstone
Dec 24, 2013·Diagnostic Microbiology and Infectious Disease·John EdelsbergDavid J Weber

❮ Previous
Next ❯

Citations

Jan 1, 2017·Infectious Diseases and Therapy·Juwon YimJason G Newland
Nov 26, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N BuettiUNKNOWN Swiss Centre for Antibiotic resistance (ANRESIS)
Nov 10, 2017·Journal of Perinatology : Official Journal of the California Perinatal Association·D F KhamashA M Milstone
Oct 9, 2019·Antimicrobial Agents and Chemotherapy·Romain BerthaudJean-Marc Tréluyer
Sep 16, 2017·Intensive Care Medicine·Andrew C ArgentSuchitra Ranjit
Jun 24, 2020·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alison C TribbleEbbing Lautenbach
Apr 13, 2019·Antimicrobial Resistance and Infection Control·Shuangshuang YangShan Sun
Dec 11, 2020·The Pediatric Infectious Disease Journal·Christian Magnus ThaulowStig Harthug
Mar 19, 2019·The Journal of Pediatrics·Rana F HamdyJeffrey S Gerber
Apr 1, 2020·Infectious Disorders Drug Targets·Panagiotis LampropoulosGabriel Dimitriou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.